This significantly revised fourth edition provides a practically orientated guide to interactions associated with antiseizure medications. It describes pharmacokinetic and pharmacodynamic antiseizure medication (ASM) interactions, including details of the magnitude and mechanism of interactions, and also of drug combinations that are not associated with interactions and therefore can be co-prescribed without undue concern. Presented in alphabetical order and by drug class, drug interactions that occur between ASMs and also between ASMs and non- ASMs are described in three sections: Drug…mehr
This significantly revised fourth edition provides a practically orientated guide to interactions associated with antiseizure medications. It describes pharmacokinetic and pharmacodynamic antiseizure medication (ASM) interactions, including details of the magnitude and mechanism of interactions, and also of drug combinations that are not associated with interactions and therefore can be co-prescribed without undue concern.
Presented in alphabetical order and by drug class, drug interactions that occur between ASMs and also between ASMs and non- ASMs are described in three sections: Drug interactions between ASMs; Drug interactions between ASMs and non- ASM Drugs: Interactions affecting ASMs; Drug interactions between ASMs and non ASM Drugs: Interactions affected by ASMs. The latest data on all drug interactions is presented. New agents discussed include cannabidiol, cenobamate, everolimus and fenfluramine,.
Antiseizure Medication Interactions:A Clinical Guide, 4th Edition concisely presents the most recent developments and data available on the topic. Therefore, enabling physicians and allied health professionals to make more rational choices when ASM polytherapy regimens are required. It will be of interest to medical professionals in disciplines including neurology, psychiatry and pediatrics.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Philip Patsalos is an Emeritus Professor of Clinical Pharmacology at University College London's Queen Square Institute of Neurology, Department of Clinical and Experimental Epilepsy, London UK. His clinical and research interests relate to the therapeutics of epilepsy and include: new drug treatments and strategies, new drug development (Phase II and III trials) and formulations, pharmacokinetic profiling and drug interactions. He has in excess of 230 publications (books, book chapters and peer reviewed papers) and has served on various International League Against Epilepsy (ILAE) committees (including the Commission on Therapeutic Strategies, the Commission on Generics, the Sub-Commission on Polytherapy and Drug Interaction and the Sub-Commission on Therapeutic Drug Monitoring) and International Association of Therapeutic Drug Monitoring and Clinical Toxicology committees (including the Clinical Pharmacokinetics Committee and the Impact of Therapeutic Drug Monitoring on Pharmacoeconomics Committee). He was recently awarded the 2016 Excellence in Epilepsy Lifetime Achievement Award by the British Branch ILAE for his contribution to epilepsy care and research.
